Given the strong causal link between cardiovascular risk and MASLD, therapeutic approaches targeting glucose and lipid metabolism have yielded promising outcomes, including insulin sensitizers, adipogenesis inhibitors, fatty acid oxidation activators, and PPAR α/γ/δ agonists. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.